Pathway Genomics Investor Says Board Ignored Assets Raid
A Curacao-based investor has hit ex-board members of defunct biotech company Pathway Genomics with a derivative shareholder suit in Delaware Chancery Court that claims they turned a blind eye to a...To view the full article, register now.
Already a subscriber? Click here to view full article